Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers.

Gustin JP, Miller J, Farag M, Rosen DM, Thomas M, Scharpf RB, Lauring J.

Oncotarget. 2017 Oct 20;8(61):103415-103427. doi: 10.18632/oncotarget.21910. eCollection 2017 Nov 28.

2.

Hydrophobically modified chitosan gauze: a novel topical hemostat.

Chaturvedi A, Dowling MB, Gustin JP, Scalea TM, Raghavan SR, Pasley JD, Narayan M.

J Surg Res. 2017 Jan;207:45-52. doi: 10.1016/j.jss.2016.04.052. Epub 2016 Jul 27.

PMID:
27979487
3.

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J.

Clin Cancer Res. 2013 Oct 1;19(19):5413-22. doi: 10.1158/1078-0432.CCR-13-0884. Epub 2013 Jul 25.

4.

Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH.

Cancer Res. 2013 Jun 1;73(11):3248-61. doi: 10.1158/0008-5472.CAN-12-1578. Epub 2013 Apr 11.

5.
6.

The growth response to androgen receptor signaling in ERĪ±-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH.

Breast Cancer Res. 2012 Feb 9;14(1):R27.

7.

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. doi: 10.1073/pnas.1110969108. Epub 2011 Oct 10.

8.

PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.

Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH.

Cancer Biol Ther. 2011 Feb 1;11(3):358-67. Epub 2011 Feb 1.

9.

Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.

Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH.

Oncogene. 2010 Apr 22;29(16):2337-45. doi: 10.1038/onc.2009.516. Epub 2010 Jan 25.

10.

Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40. doi: 10.1073/pnas.0813351106. Epub 2009 Feb 5.

11.

The PIK3CA gene as a mutated target for cancer therapy.

Gustin JP, Cosgrove DP, Park BH.

Curr Cancer Drug Targets. 2008 Dec;8(8):733-40. Review.

12.

Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):288-93. Epub 2007 Dec 27.

13.

A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting.

Konishi H, Lauring J, Garay JP, Karakas B, Abukhdeir AM, Gustin JP, Konishi Y, Park BH.

Nat Protoc. 2007;2(11):2865-74.

PMID:
18007621
14.

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH.

Blood. 2008 Jan 15;111(2):856-64. Epub 2007 Oct 17.

15.

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, Park BH.

Cancer Res. 2007 Sep 15;67(18):8460-7.

16.

P21 gene knock down does not identify genetic effectors seen with gene knock out.

Karakas B, Weeraratna AT, Abukhdeir AM, Konishi H, Gustin JP, Vitolo MI, Bachman KE, Park BH.

Cancer Biol Ther. 2007 Jul;6(7):1025-30.

17.

Vesicle--biopolymer gels: networks of surfactant vesicles connected by associating biopolymers.

Lee JH, Gustin JP, Chen T, Payne GF, Raghavan SR.

Langmuir. 2005 Jan 4;21(1):26-33.

PMID:
15620281

Supplemental Content

Loading ...
Support Center